Indacaterol (Onbrez® Basel, Switzerland), previously known as QAB-149-AFA, is a novel ultra-long-acting β2-adreno- ceptor agonist that was recently approved by the European Commission as a new once-daily maintenance bron- chodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). COPD is a major cause of chronic morbidity worldwide. According to World Health Organisation, it was the fifth cause of death in 2002 and it is projected to be the fourth cause of mortality by 2030. The rapid onset of action of indacaterol, duration of bronchodilation for at least 24 hours, and an optimal safety profile make this drug an interesting and attractive weapon for its use in fight against the COPD.
Indacaterol for Chronic Obstructive Pulmonary Disease.
PROIETTO, ALFIO;
2010-01-01
Abstract
Indacaterol (Onbrez® Basel, Switzerland), previously known as QAB-149-AFA, is a novel ultra-long-acting β2-adreno- ceptor agonist that was recently approved by the European Commission as a new once-daily maintenance bron- chodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). COPD is a major cause of chronic morbidity worldwide. According to World Health Organisation, it was the fifth cause of death in 2002 and it is projected to be the fourth cause of mortality by 2030. The rapid onset of action of indacaterol, duration of bronchodilation for at least 24 hours, and an optimal safety profile make this drug an interesting and attractive weapon for its use in fight against the COPD.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
